{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":19,"sponsored":0,"items":[{"id":"n_rccnpjj5twyechhicfea","seq":1422593,"kind":"article","title":"Merck stops making Recarbrio, highlighting tricky landscape for new antibiotics","url":"https://www.healio.com/news/infectious-disease/20261002/merck-stops-making-recarbrio-highlighting-tricky-landscape-for-new-antibiotics","summary":"Merck has decided to discontinue production of a combination antibiotic used in hospitals to target life-threatening infections resistant to other medications. The drug company told Healio the decision to pull Recarbrio off the U.S. market was part of an “ongoing portfolio review” and not based on product safety or quality issues. It expected the remaining inventory to be depleted by the end of last month. “We understand that Recarbrio has been an important option for…","published":"2026-10-02T19:39:15Z","seen":"2026-10-02T20:17:22Z","lang":"en","source":{"id":"kite-healio-com-23151b","name":"healio.com","domain":"healio.com"},"via":"kite-healio-com-23151b","topics":["medicine"],"authors":["Anthony Stitt"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q65648491","name":"imipenem/cilastatin/relebactam","type":"other"}],"mentions":2,"story":"st_3vrothd66ymdjmtc55xq","category":"economy-business","category_p":0.49,"sentiment":"neutral","tone":-0.38,"political":0.18},{"id":"n_24y6t4leytuhmudg3t5q","seq":824421,"kind":"article","title":"Merck pulls antibiotic for multidrug-resistant infections from US market","url":"https://www.cidrap.umn.edu/antimicrobial-stewardship/merck-pulls-antibiotic-multidrug-resistant-infections-us-market","published":"2026-09-30T04:52:20Z","seen":"2026-09-30T04:52:20Z","lang":"en","source":{"id":"umn.edu","name":"umn.edu","domain":"umn.edu","outlet":{"wikidata":"Q14552696","name":"University of Minnesota System","type":"other","country":"US","designations":["state university system"]}},"via":"gdelt-gkg-english","topics":["politics","economy","health","education"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"}],"story":"st_u53oj4kpwbrkhwnvlhua","category":"health","category_p":0.47,"category2":"economy-business","sentiment":"negative","tone":-0.45,"political":0.16},{"id":"n_nym7t7ml65i243e4vsfq","seq":823389,"kind":"article","title":"Merck and Daiichi Withdraw Small Cell Lung Cancer Drug Bid After FDA Signals Phase 2 Data Fell Short","url":"https://www.medicaldaily.com/merck-daiichi-ifinatamab-deruxtecan-sclc-application-withdrawn-479280","summary":"Merck and Daiichi pulled their bid for accelerated approval of I-DXd in small-cell lung cancer after FDA feedback. What patients should ask now.","published":"2026-09-30T04:17:45Z","seen":"2026-09-30T04:49:13Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q49107945","name":"Best Denki (Taiwan)","type":"org"}],"mentions":2,"story":"st_nym7t7ml65i243e4vsfq","category":"health","category_p":0.49,"category2":"economy-business","sentiment":"negative","tone":-0.5,"political":0.22},{"id":"n_u53oj4kpwbrkhwnvlhua","seq":791518,"kind":"article","title":"Merck pulls antibiotic from US market","url":"https://www.cidrap.umn.edu/antimicrobial-stewardship/merck-pulls-antibiotic-us-market","published":"2026-09-30T00:00:00Z","seen":"2026-09-30T00:04:24Z","lang":"en","source":{"id":"umn.edu","name":"umn.edu","domain":"umn.edu","outlet":{"wikidata":"Q14552696","name":"University of Minnesota System","type":"other","country":"US","designations":["state university system"]}},"via":"gdelt-gkg-english","topics":["economy","education","health","politics"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"}],"story":"st_u53oj4kpwbrkhwnvlhua","category":"health","category_p":0.41,"category2":"economy-business","sentiment":"negative","tone":-0.43,"political":0.25},{"id":"n_whgmoqziwotrr6tlxhxa","seq":770825,"kind":"article","title":"Merck highlights new technology to monitor calf behavior","url":"https://www.brownfieldagnews.com/news/merck-highlights-new-technology-to-monitor-calf-behavior","summary":"Merck Animal Health is highlighting new releases at the World Dairy Expo this week. Associate director for dairy monitoring Chase Milem says SenseHub Dairy Youngstock Monitoring empowers producers to grow strong replacements. “We’re monitoring the behavior of calves.” He tells Brownfield they’ve expanded the system beyond bottle-fed calves. “So no matter how they’re feeding their […] The post Merck highlights new technology to monitor calf behavior appeared first on…","published":"2026-09-29T20:41:01Z","seen":"2026-09-29T21:28:20Z","lang":"en","source":{"id":"kite-brownfieldagnews-com-ca786a","name":"brownfieldagnews.com","domain":"brownfieldagnews.com"},"via":"kite-brownfieldagnews-com-ca786a","topics":["agriculture","2026 events","2026 world dairy expo","dairy","news","animal ag","livestock","merck animal health"],"authors":["Mark Dorenkamp"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"}],"story":"st_whgmoqziwotrr6tlxhxa","category":"science-technology","category_p":0.38,"category2":"health","sentiment":"neutral","tone":0.16,"political":0.02},{"id":"n_kep7422v6w4xdjerfq7a","seq":736058,"kind":"article","title":"首付款4亿美元 默沙东买下中国一款在研临床前口服药","title_en":"Merck buys a pre-clinical oral drug under research in China for $400 million","url":"http://baijiahao.baidu.com/s?id=1877652034334439329","published":"2026-09-29T17:48:23Z","seen":"2026-09-29T17:48:23Z","lang":"zh","country":"CN","source":{"id":"kite-news-baidu-com-c52b23","name":"news.baidu.com","domain":"news.baidu.com"},"via":"kite-news-baidu-com-c52b23","entities":[{"id":"Q96472579","name":"Merck","type":"org"}],"story":"st_kep7422v6w4xdjerfq7a","category":"economy-business","category_p":0.91,"sentiment":"positive","tone":0.4,"political":0.17},{"id":"n_c5k7rhjnmzry2ecahlha","seq":712544,"kind":"article","title":"Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year","url":"https://www.aol.com/articles/merck-turned-1-000-3-152755000.html","published":"2026-09-29T15:27:00Z","seen":"2026-09-29T15:55:53Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["business","economy","health"],"authors":["AOL"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"}],"story":"st_c5k7rhjnmzry2ecahlha","category":"economy-business","category_p":0.87,"sentiment":"positive","tone":0.07,"political":0.01},{"id":"n_psitonzhfxu7qknafg4a","seq":669745,"kind":"article","title":"鉅亨速報 - Factset 最新調查：默克藥廠MRK-US的目標價調升至160元，幅度約3.23%","title_en":"Factset's latest survey: Merck's target price raised to 160, up about 3.23%","url":"https://news.cnyes.com/news/id/6618087","summary":"根據FactSet最新調查，共25位分析師，對默克藥廠(MRK-US)提出目標價估值：中位數由155元上修至160元，調升幅度3.23%。其中最高估值186元，最低估值105元。綜合評級 - 共有31位分析師給予默克藥廠評價：積極樂觀21位、保持中立9位、保守悲觀1位。默克藥廠今(29日)收盤價為1","published":"2026-09-29T12:15:25Z","seen":"2026-09-29T12:40:50Z","lang":"zh","country":"TW","source":{"id":"kite-news-cnyes-com-887ba2","name":"news.cnyes.com","domain":"news.cnyes.com"},"via":"kite-news-cnyes-com-887ba2","topics":["美股預估"],"authors":["鉅亨網新聞中心"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"}],"image":"https://cimg.cnyes.cool/static/rss/default/m/02.jpg","story":"st_psitonzhfxu7qknafg4a","category":"economy-business","category_p":0.83,"sentiment":"neutral","tone":0.11,"political":0.04},{"id":"n_hmv726gj4e24ig6slffa","seq":628272,"kind":"press_release","title":"Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer","url":"https://www.globenewswire.com/news-release/2026/09/29/3370541/28124/en/small-molecule-drug-discovery-global-strategic-business-report-forecasts-growth-from-61-5b-2024-to-100b-by-2030-profiling-astrazeneca-gilead-sciences-merck-pfizer.html","summary":"AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities. AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities.","published":"2026-09-29T09:22:00Z","seen":"2026-09-29T09:30:50Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q731938","name":"AstraZeneca","type":"org"},{"id":"Q663596","name":"Gilead Sciences","type":"org"},{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q206921","name":"Pfizer","type":"org"}],"story":"st_hmv726gj4e24ig6slffa","category":"economy-business","category_p":0.72,"sentiment":"neutral","tone":0.27,"political":0.01},{"id":"n_hu36rnwnifxecvskjija","seq":632564,"kind":"article","title":"AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows","url":"https://www.scmp.com/business/china-business/article/3369187/astrazeneca-merck-novo-deals-boost-chinese-biotech-global-interest-grows","summary":"Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit…","published":"2026-09-29T09:00:07Z","seen":"2026-09-29T09:45:53Z","lang":"en","source":{"id":"kite-scmp-com-62b166","name":"scmp.com","domain":"scmp.com","outlet":{"wikidata":"Q1198574","name":"South China Morning Post","type":"newspaper","country":"CN","designations":["daily newspaper","online newspaper"]}},"via":"kite-scmp-com-62b166","topics":["asia"],"authors":["author","Xinmei Shen"],"entities":[{"id":"Q731938","name":"AstraZeneca","type":"org"},{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q818846","name":"Novo","type":"org"}],"image":"https://cdn.i-scmp.com/sites/default/files/styles/1280x720/public/d8/images/canvas/2026/09/29/7f6c4329-d288-4727-beb9-619f8c34c411_3c3f6fa8.jpg?itok=z4ByUngy&v=1790670041","mentions":2,"story":"st_hu36rnwnifxecvskjija","category":"economy-business","category_p":0.79,"sentiment":"positive","tone":0.78,"political":0.15},{"id":"n_dlvl3vc2iuwfkp5e7acq","seq":567698,"kind":"article","title":"Merck (MRK) Withdrew a Cancer Filing. Is the Drug's Promise Still Intact?","url":"https://www.insidermonkey.com/news/merck-mrk-withdrew-a-cancer-filing-is-the-drugs-promise-still-intact-1845076","published":"2026-09-29T03:15:00Z","seen":"2026-09-29T03:19:19Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["business","health","economy"],"authors":["Jeff Lewis"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"}],"story":"st_dlvl3vc2iuwfkp5e7acq","category":"health","category_p":0.52,"category2":"economy-business","sentiment":"neutral","tone":-0.26,"political":0.14},{"id":"n_e34rtx5ueloa3hzkq5wq","seq":521788,"kind":"article","title":"STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance","url":"https://www.statnews.com/pharmalot/2026/09/28/merck-discontinues-antibiotic-recarbrio-in-u-s-despite-superbug-concerns","summary":"Merck discontinued Recarbio, an important antibiotic in the U.S., despite concerns over resistance to superbugs.","published":"2026-09-28T20:45:43Z","seen":"2026-09-28T21:01:21Z","lang":"en","country":"US","source":{"id":"kite-statnews-com-165bdc","name":"statnews.com","domain":"statnews.com","outlet":{"wikidata":"Q28452506","name":"Stat","type":"website","designations":["business","news website","website"]}},"via":"kite-statnews-com-165bdc","topics":["healthcare","usa","pharmalot","biotechnology","drug development","pharmaceuticals","policy","public health"],"authors":["Ed Silverman"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"}],"image":"https://www.statnews.com/wp-content/uploads/2017/01/14342-645x645.jpg","mentions":2,"story":"st_e34rtx5ueloa3hzkq5wq","category":"health","category_p":0.44,"category2":"economy-business","sentiment":"negative","tone":-0.5,"political":0.24},{"id":"n_gxydz22o7sk6ohnqlsca","seq":486499,"kind":"article","title":"Merck, Daiichi end plans to seek speedy approval of lung cancer ADC","url":"https://www.biopharmadive.com/news/merck-daiichi-fda-withdraw-ifinatamab-deruxtecan-sclc/831440","published":"2026-09-28T17:40:29Z","seen":"2026-09-28T17:40:29Z","lang":"en","source":{"id":"biopharmadive.com","name":"biopharmadive.com","domain":"biopharmadive.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["Ben Fidler"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q49107945","name":"Best Denki (Taiwan)","type":"org"}],"story":"st_gxydz22o7sk6ohnqlsca","category":"health","category_p":0.53,"category2":"economy-business","sentiment":"neutral","tone":-0.28,"political":0.27},{"id":"n_rpclha2zq7secvaz4ova","seq":462296,"kind":"article","title":"Merck pens $2.1B deal with China's SciBrunch to chase KRAS G12D","url":"https://www.fiercebiotech.com/biotech/merck-pens-21b-deal-chinas-scibrunch-chase-kras-g12d","published":"2026-09-28T15:23:25Z","seen":"2026-09-28T15:23:25Z","lang":"en","source":{"id":"fiercebiotech.com","name":"fiercebiotech.com","domain":"fiercebiotech.com"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q29520","name":"China","type":"place"}],"story":"st_rpclha2zq7secvaz4ova","category":"economy-business","category_p":0.7,"sentiment":"neutral","tone":0.08,"political":0.45},{"id":"n_t7qzjginxvdrgypogqyq","seq":442571,"kind":"article","title":"STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more","url":"https://www.statnews.com/pharmalot/2026/09/28/glp1-lifestyle-drug-marketing-merck-daiichi-lung-cancer-setback","summary":"Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel better","published":"2026-09-28T13:06:52Z","seen":"2026-09-28T13:53:49Z","lang":"en","country":"US","source":{"id":"kite-statnews-com-aa5345","name":"statnews.com","domain":"statnews.com","outlet":{"wikidata":"Q28452506","name":"Stat","type":"website","designations":["business","news website","website"]}},"via":"kite-statnews-com-aa5345","topics":["healthcare","usa","medicine","pharma","pharmalot","pharmalittle","stat+"],"authors":["Ed Silverman"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q49107945","name":"Best Denki (Taiwan)","type":"org"}],"image":"https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg","mentions":2,"story":"st_t7qzjginxvdrgypogqyq","category":"health","category_p":0.41,"category2":"economy-business","sentiment":"neutral","tone":-0.09,"political":0.1},{"id":"n_bcyu5cbkn6nh4rlurqxa","seq":399145,"kind":"article","title":"Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal","url":"https://www.fiercebiotech.com/biotech/merck-co-and-daiichi-pull-lung-cancer-filing-after-fda-pushback-deals-another-blow-4b-deal","published":"2026-09-28T10:22:05Z","seen":"2026-09-28T10:22:05Z","lang":"en","source":{"id":"fiercebiotech.com","name":"fiercebiotech.com","domain":"fiercebiotech.com"},"via":"gdelt-gkg-english","topics":["economy","science"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q49107945","name":"Best Denki (Taiwan)","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_bcyu5cbkn6nh4rlurqxa","category":"economy-business","category_p":0.71,"sentiment":"negative","tone":-0.69,"political":0.4},{"id":"n_qchulpknp4cej3oincvq","seq":383800,"kind":"press_release","title":"Global Cell Line Generation Market Outlook, 2026-2032 - AI, CRISPR and Automation Fuel 10.86% CAGR, Driving the Market to USD 2.67 Billion as Thermo Fisher Scientific, Lonza, Merck and WuXi Biologics Advance Innovation","url":"https://www.globenewswire.com/news-release/2026/09/28/3369609/28124/en/global-cell-line-generation-market-outlook-2026-2032-ai-crispr-and-automation-fuel-10-86-cagr-driving-the-market-to-usd-2-67-billion-as-thermo-fisher-scientific-lonza-merck-and-wux.html","summary":"Boost ROI through standardized QC, auditable automation, validated AI, diversified reagent sourcing, regional partnerships, and cross-skilled workforce training Boost ROI through standardized QC, auditable automation, validated AI, diversified reagent sourcing, regional partnerships, and cross-skilled workforce training","published":"2026-09-28T09:03:00Z","seen":"2026-09-28T09:11:43Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q30260387","name":"FEI (Japan)","type":"org"},{"id":"Q672715","name":"Lonza","type":"org"},{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q85816338","name":"WuXi Biologics","type":"org"}],"story":"st_qchulpknp4cej3oincvq","category":"economy-business","category_p":0.69,"category2":"science-technology","sentiment":"positive","tone":0.43,"political":0.02},{"id":"n_bn6xe2ksgw2zkcvlahnq","seq":394352,"kind":"article","title":"Daiichi, Merck Withdraw U.S. Filing For Lung Cancer Drug Ifinatamab Deruxteca","url":"https://www.rttnews.com/3694229/daiichi-merck-withdraw-u-s-filing-for-lung-cancer-drug-ifinatamab-deruxteca.aspx","published":"2026-09-28T08:51:00Z","seen":"2026-09-28T09:53:18Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"entities":[{"id":"Q49107945","name":"Best Denki (Taiwan)","type":"org"},{"id":"Q96472579","name":"Merck","type":"org"}],"story":"st_bn6xe2ksgw2zkcvlahnq","category":"health","category_p":0.46,"sentiment":"neutral","tone":-0.5,"political":0.45},{"id":"n_7lb5b7uhigojukyklulq","seq":321847,"kind":"article","title":"머크·다이이찌산쿄, 폐암 신약 'Ifinatamab Deruxtecan' FDA 허가 신청 철회","title_en":"Merck and Daiichi Sankyo withdraw FDA approval application for new lung cancer drug 'Ifinatamab Deruxtecan'","url":"https://www.pharmnews.com/news/articleView.html?idxno=306528","summary":"[팜뉴스=우정민 기자] 머크와 다이이찌산쿄가 폐암 치료제의 미국 허가 신청을 철회했다. 25일(현지시간) 양사는 백금 기반 화학요법 치료 후 병이 진행된 진전기 소세포폐암 환자용 항체-약물 접합체(ADC) \\'Ifinatamab Deruxtecan, I-DXd\\'의 생물학적 제제 품목허가를 취소한다고 밝혔다.당초 2026년 4월 미국 식품의약국(FDA)으로부터 우선심사 대상으로 지정돼 오는 10월 10일 최종 승인 여부 결정을 앞두고 있었으나, 임상 2상 데이터만으로는 신속 승인 기준을 충족하기 어렵다는 당국의 의견을 반영한 결정이다.","published":"2026-09-28T00:11:46Z","seen":"2026-09-28T01:33:18Z","lang":"ko","source":{"id":"kite-cdn-pharmnews-com-3e2457","name":"cdn.pharmnews.com","domain":"cdn.pharmnews.com"},"via":"kite-cdn-pharmnews-com-3e2457","topics":["medicine","산업"],"authors":["우정민 기자"],"entities":[{"id":"Q96472579","name":"Merck","type":"org"},{"id":"Q669441","name":"Daiichi Sankyo","type":"org"},{"id":"Q123582114","name":"ifinatamab deruxtecan","type":"other"}],"story":"st_7lb5b7uhigojukyklulq","category":"health","category_p":0.4,"category2":"politics","sentiment":"neutral","tone":-0.35,"political":0.52}]}